Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus–Specific CD8 T-Cell Responses and High Anti–Hepatitis B Surface Antigen Titers
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiad340 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Sarah Schmidt und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hookipa Pharma, New York, New York, USA. Hauptthemen laut MEDLINE: Arenavirus, Hepatitis B. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Hepatitis B Virus (HBV) is a major driver of infectious disease mortality. Curative therapies are needed and ideally should induce CD8 T cell-mediated clearance of infected hepatocytes plus anti-hepatitis B surface antigen (HBsAg) antibodies (anti-HBs) to neutralize residual virus. We developed a novel therapeutic vaccine using non-replicating arenavirus vectors. Antigens were screened for genotype conservation and magnitude and genotype reactivity of T cell response, then cloned into Pichinde virus (PICV) vectors (recombinant PICV, GS-2829) and lymphocytic choriomeningitis virus (LCMV) vectors (replication-incompetent, GS-6779). Alternating immunizations with GS-2829 and GS-6779 induced high-magnitude HBV T cell responses, and high anti-HBs titers. Dose schedule optimization in macaques achieved strong polyfunctional CD8 T cell responses against core, HBsAg, and polymerase and high titer anti-HBs. In AAV-HBV mice, GS-2829 and GS-6779 were efficacious in animals with low pre-treatment serum HBsAg. Based on these results, GS-2829 and GS-6779 could become a central component of cure regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hookipa Pharma, New York, New York, USA.
- Gilead Sciences, Foster City, California, USA.
- Department of Immunology and Microbial Disease, Albany Medical College, Albany, New York, USA.
Förderung
- Gilead Sciences
Zitieren
APA
Schmidt, S., Mengistu, M., Daffis, S., Ahmadi-Erber, S., Deutschmann, D., Grigoriev, T., Chu, R., Leung, C., Tomkinson, A., Uddin, M. N., Moshkani, S., Robek, M. D., Perry, J., Lauterbach, H., Orlinger, K., Fletcher, S. P., & Balsitis, S. (2024). Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus–Specific CD8 T-Cell Responses and High Anti–Hepatitis B Surface Antigen Titers. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad340
Vancouver
Schmidt S, Mengistu M, Daffis S, Ahmadi-Erber S, Deutschmann D, Grigoriev T, et al. Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus–Specific CD8 T-Cell Responses and High Anti–Hepatitis B Surface Antigen Titers. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad340
BibTeX
@article{Schmidt2024,
author = {Schmidt, Sarah and Mengistu, Meron and Daffis, Stephane and Ahmadi-Erber, Sarah and Deutschmann, Daniela and Grigoriev, Tetiana and Chu, Ruth and Leung, Cleo and Tomkinson, Adrian and Uddin, Mohammad Nizam and Moshkani, Safiehkhatoon and Robek, Michael D and Perry, Jason and Lauterbach, Henning and Orlinger, Klaus and Fletcher, Simon P and Balsitis, Scott},
title = {Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus–Specific CD8 T-Cell Responses and High Anti–Hepatitis B Surface Antigen Titers},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiad340}
}
EUVIMED